Immunic Inc (NASDAQ:IMUX) shares, rose in value on Thursday, April 16, with the stock price up by 3.98% to the previous day’s close as strong demand from buyers drove the stock to $0.98.
Actively observing the price movement in the last trading, the stock closed the session at $0.94, falling within a range of $0.94 and $0.98. The value of beta (5-year monthly) was 1.915. Referring to stock’s 52-week performance, its high was $2.11, and the low was $0.83. On the whole, IMUX has fluctuated by -15.52% over the past month.
With the market capitalization of Immunic Inc currently standing at about $93.90 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-30.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that IMUX’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of IMUX currently trading nearly -6.20% and -9.35% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 45.25, while the 7-day volatility ratio is showing 8.08% which for the 30-day chart, stands at 8.73%. Furthermore, Immunic Inc (IMUX)’s beta value is 1.72, and its average true range (ATR) is 0.09.
A comparison of Immunic Inc (IMUX) with its peers suggests the former has fared considerably weaker in the market. IMUX showed an intraday change of 3.98% in last session, and over the past year, it shrunk by -23.44%%.
Data on historical trading for Immunic Inc (NASDAQ:IMUX) indicates that the trading volumes over the past 10 days have averaged 0.59 and over the past 3 months, they’ve averaged 815.20K. According to company’s latest data on outstanding shares, there are 95.82 million shares outstanding.
Nearly 3.02% of Immunic Inc’s shares belong to company insiders and institutional investors own 51.71% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.02 million shares as on 2025-03-31, resulting in a short ratio of 3.25. According to the data, the short interest in Immunic Inc (IMUX) stood at 226.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.4 million. The stock has fallen by -2.00% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the IMUX stock heading into the next quarter.
